Taylor Frigon Capital Management LLC - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 168 filers reported holding NOVOCURE LTD in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 0.2%.

Quarter-by-quarter ownership
Taylor Frigon Capital Management LLC ownership history of NOVOCURE LTD
ValueSharesWeighting
Q2 2024$2,283,395
+15.1%
133,298
+5.0%
1.09%
+15.0%
Q1 2024$1,983,666
+37.2%
126,914
+31.0%
0.94%
+30.2%
Q4 2023$1,446,075
-2.1%
96,857
+5.9%
0.73%
-11.6%
Q3 2023$1,476,675
-46.6%
91,435
+37.2%
0.82%
-39.2%
Q2 2023$2,765,768
+11.1%
66,645
+61.0%
1.35%
-0.7%
Q1 2023$2,489,856
-19.3%
41,401
-1.6%
1.36%
-22.3%
Q4 2022$3,085,174
-9.6%
42,061
-6.4%
1.75%
-1.6%
Q3 2022$3,413,000
-28.7%
44,918
-34.8%
1.78%
-28.6%
Q2 2022$4,789,000
-20.8%
68,908
-5.6%
2.49%
+11.0%
Q1 2022$6,049,000
+73.7%
73,014
+57.4%
2.24%
+105.8%
Q4 2021$3,482,000
-34.6%
46,376
+1.2%
1.09%
-36.5%
Q3 2021$5,326,000
-22.6%
45,848
+47.7%
1.72%
-20.2%
Q2 2021$6,884,000
+7.1%
31,035
-36.2%
2.15%
+8.5%
Q1 2021$6,430,000
-24.1%
48,649
-0.7%
1.98%
-28.8%
Q4 2020$8,477,000
+62.4%
48,990
+4.5%
2.78%
+21.0%
Q3 2020$5,220,000
+90.1%
46,896
+1.3%
2.30%
+68.6%
Q2 2020$2,746,000
-48.2%
46,304
-41.2%
1.36%
-38.7%
Q1 2020$5,305,000
+65.4%
78,780
+106.9%
2.23%
+0.7%
Q4 2019$3,208,000
+4.1%
38,073
-7.6%
2.21%
-0.8%
Q3 2019$3,081,000
+4.6%
41,198
-11.6%
2.23%
+9.1%
Q2 2019$2,946,000
+43.9%
46,599
+9.7%
2.04%
+28.4%
Q1 2019$2,047,000
+39.9%
42,489
-2.7%
1.59%
+23.7%
Q4 2018$1,463,00043,6861.29%
Other shareholders
NOVOCURE LTD shareholders Q4 2018
NameSharesValueWeighting ↓
Nordwand Advisors, LLC 1,515,000$25,951,95011.32%
Invus Financial Advisors, LLC 350,884$6,010,6436.74%
SUPERSTRING CAPITAL MANAGEMENT LP 66,892$1,145,8601.44%
Palo Alto Investors LP 561,908$9,625,4841.12%
Taylor Frigon Capital Management LLC 133,298$2,283,3951.09%
ESSEX INVESTMENT MANAGEMENT CO LLC 161,486$2,766,2550.52%
Birchview Capital, LP 20,000$342,6000.32%
PDT Partners, LLC 188,422$3,227,6690.31%
FRONTIER CAPITAL MANAGEMENT CO LLC 1,028,331$17,615,3120.17%
Soleus Capital Management, L.P. 108,900$1,865,4570.16%
View complete list of NOVOCURE LTD shareholders